# A First-in-human Study of BGB-53038, a Pan-KRAS Inhibitor, Alone or in Combinations in Participants With Advanced or Metastatic Solid Tumors With KRAS Mutations or Amplification

> **NCT06585488** · PHASE1 · RECRUITING · sponsor: **BeiGene** · enrollment: 514 (estimated)

## Conditions studied

- Metastatic Solid Tumors
- Advanced Non-squamous Non-small-cell Lung Cancer
- Advanced Colorectal Cancer
- Advanced Pancreatic Ductal Adenocarcinoma
- Advanced Gastric Cancer
- Advanced Gastroesophageal Junction Cancer
- Advanced Esophageal Adenocarcinoma

## Interventions

- **DRUG:** BGB-53038
- **DRUG:** Tislelizumab
- **DRUG:** Cetuximab

## Key facts

- **NCT ID:** NCT06585488
- **Lead sponsor:** BeiGene
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-11-26
- **Primary completion:** 2026-12
- **Final completion:** 2026-12
- **Target enrollment:** 514 (ESTIMATED)
- **Last updated:** 2026-03-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06585488

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06585488, "A First-in-human Study of BGB-53038, a Pan-KRAS Inhibitor, Alone or in Combinations in Participants With Advanced or Metastatic Solid Tumors With KRAS Mutations or Amplification". Retrieved via AI Analytics 2026-08-11 from https://api.ai-analytics.org/clinical/NCT06585488. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*